Gastric cancer remains a major global public health problem[@b1][@b2][@b3]. Although the incidence of gastric cancer has been declining, it remains the fifth most frequently diagnosed cancer and the second leading cause of cancer-related death worldwide[@b4][@b5]. Unfortunately, it is often diagnosed at an advanced stage and is associated with poor survival. Radical surgery remains the only potential curative modality for patients with resected gastric cancer. Remarkably, the incidence of gastric cancer is the highest in China[@b6].

The number of metastatic lymph nodes (LNs; pN stage) is considered one of the most reliable prognostic indicators for patients with radically resected gastric cancer. The International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) N staging system depends on an adequate number (≥15) of metastatic LNs retrieved[@b7][@b8]. The Japanese Gastric Cancer Association (JGCA) N staging system depends on the level of metastatic LNs - at least second-level (D2 lymphadenectomy) for optimal staging[@b9]. However, both the UICC/AJCC N staging system and the JGCA N staging system depend on ≥15 LNs for optimal staging.

A more extensive LN dissection may contribute to more LNs retrieved, which may also improve staging accuracy. However, its contribution to prolonged survival remains unclear; much of the survival benefit associated with extensive lymphadenectomy may only be due to stage migration ("Will Rogers" effect)[@b10][@b11][@b12][@b13]. Moreover, more extensive surgery can also contribute to more operation-related complications and mortality. Therefore, the efficacy of various LN dissection levels remains controversial[@b7][@b11][@b14][@b15].

Gastrectomy with D1 or modified D2 lymphadenectomy, with a goal of ≥15 LNs retrieved has been recommended for patients with localized resected gastric cancer in western countries[@b7][@b11][@b15]. Recently, standard D2 lymphadenectomy has become the standard treatment for curable gastric cancer in eastern Asia, especially in Japan and China. However, previous studies have shown that a more extensive LN dissection improves survival in patients with advanced gastric cancer[@b11][@b12][@b16]. Extended D2 (D2+) lymphadenectomy may help to retrieve more LNs for patients with gastric cancer compared with D2 lymphadenectomy, which may contribute to adequate staging and a beneficial survival outcome. To our knowledge, there is no study comparing survival after D2 and D2+ lymphadenectomy for locally advanced gastric cancer with distal subtotal gastrectomy. In light of these considerations, we aimed to investigate prognosis and survival of patients undergoing distal subtotal gastrectomy with D2 and D2+ lymphadenectomy for patients with locally advanced gastric cancer.

Patients and Methods
====================

All patients with advanced gastric cancer who underwent surgery in our institution were entered into a retrospectively maintained database between February 1990 and February 2014. A total of 424 patients with locally advanced gastric cancer patients underwent distal subtotal gastrectomy with D2 or D2+ lymphadenectomy, and achieved a potentially curative resection for histologically proven gastric carcinoma. Moreover, patients with pre-operative chemo-radiation or chemotherapy were excluded in this study.

This study was approved by the Ethics Committee of the Fourth Affiliated Hospital, China Medical University. All patient records and information were anonymized and de-identified prior to analysis. The methods were carried out in "accordance" with the approved guidelines. We confirm that informed consent was obtained from all subjects.

The follow-up period of the entire population was complete until death or the cutoff date of October 2014. All patients underwent history and physical examination, and had CEA and CA19--9 levels assessed every 3 to 6 months for the first postoperative year, and every 6 to 12 months thereafter. The median and mean follow-up durations were 36 and 62 months, respectively (range 1--286 months). Eight patients were lost to follow-up and were excluded from this study. The rate of follow-up was 98.1%.

Of the included 416 patients with locally advanced gastric cancer, 287 (69.0%) underwent D2 lymphadenectomy. An average of 18.35 ± 9.72 LNs were retrieved, with 4.92 ± 5.01 metastatic LNs. One-hundred and twenty-nine (31.0%) patients underwent D2+ lymphadenectomy, with an average of 20.80 ± 10.38 retrieved LNs and 5.37 ± 6.86 metastatic LNs.

Only patients with locally advanced gastric cancer in stage II and stage III (pT2--4aN0--3M0: including, T3N0M0, T2N1M0, T4aN0M0, T3N1M0, T2N2M0, T4aN1M0, T3N2M0, T2N3M0, T4aN2M0, T3N3M0, and T4aN3M0) were included in this study (T2, tumor invades muscularis propria; T3, tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures; T4a, invades serosa; N0, no regional LNs metastasis; N1, 1--2 regional LNs metastasis; N2, 3--6 regional LNs metastasis; N3, ≥7 regional LNs metastasis)[@b8].

According to the National Comprehensive Cancer Network (NCCN) guidelines for gastric cancer, D2 lymphadenectomy should include regional LNs (perigastric LNs) and those along the named vessels of the celiac axis (left gastric artery, common hepatic artery, celiac artery, splenic hilum, and splenic artery)[@b8]. For distal subtotal gastrectomy, D2 lymphadenectomy includes No. 1, No. 3, No. 4sb, No. 4d, No. 5, No. 6, No. 7, No. 8a, No. 9, No. 11p, and No. 12a LNs. D2+ lymphadenectomy includes LNs of D2 and one or more of these LNs, including, No. 8p, No. 12b, No. 13, and No. 14v LNs.

D2+ lymphadenectomy was recommended for patients who were highly suspected with level 2 LN metastasis, preoperatively, according to contrast-enhanced computed tomograph (CT) scans of the abdomenm, preoperatively. Moreover, D2+ lymphadenectomy was also recommended for patients who were highly suspected with level 2 LN metastasis, according to the macroscopic appearance of level 2 LNs, intraoperatively. Importantly, D2+ lymphadenectomy was recommended if level 2 LN metastasis was proved by pathology detection, intraoperatively.

Recurrences were classified as locoregional recurrence and distant recurrence. Locoregional recurrence included any cancer recurrence in gastric bed, anastomotic sites, and regional LNs. Distant recurrence included visceral metastases, peritoneal metastases, and LN metastases beyond the regional LNs. Importantly, all recurrences were diagnosed clinically or radiographically, with histopathologic test or radiographic test, including CT of head, chest, abdomen, and pelvis; bone scans, or even positron emission tomography-CT (PET-CT) would be applied if necessary. Moreover, the incidence of each pattern of recurrence was compared between patients with D2 lymphadenectomy and D2+ lymphadenectomy. ([Table 1](#t1){ref-type="table"})

The carcinoma lesions together with the surrounding gastric wall were fixed in formalin and cut into multiple 5 mm slices, which were parallel to the lesser curvature; two pathologists independently examined the sections and disagreements were resolved by discussion to determine the final diagnosis. According to the current NCCN guidelines for gastric cancer, examining at least 15 LNs was strongly recommended for adequate staging[@b7][@b11]. Thus, if fewer than 15 LNs are initially identified, resubmission should be performed in order to identify as many LNs as possible.

Overall survival rates were calculated using Kaplan-Meier survival analysis. An event was defined as death for a cancer-related cause. Two sided χ^2^ tests or two-tailed t-tests were performed for statistical comparison of clinicopathologic features between patients with D2 and D2+ lymphadenectomy. The log-rank test was conducted in the univariate analysis and multivariate analysis was used to identify significant prognostic factors correlated with LN metastasis. Cox's proportional hazard model was applied to identify significant factors correlating with prognosis, according to the results of the univariate analysis. Scatter diagrams were used for distribution of metastatic LNs and retrieved LNs, between D2 and D2+ lymphadenectomy. A p-value of less than 0.05 was defined as statistically significant. SPSS version 20.0 statistical software was used for statistical analysis (SPSS Inc., Chicago, IL, USA).

Results
=======

A total of 416 patients with locally advanced gastric cancer who underwent distal subtotal gastrectomy were included in this study. Of these, 287 patients (median age 58.61 ± 10.63 years) underwent D2 lymphadenectomy and 129 patients (median age 57.86 ± 11.07 years) underwent D2+ lymphadenectomy. For patients who underwent D2 lymphadenectomy, 81 (28.2%) were female and 206 (71.8%) were male. For patients who underwent D2+ lymphadenectomy, 48 (37.2%) were female and 81 (62.8%) were male.

Clinicopathologic features were comparable between patients undergoing D2 and D2+ lymphadenectomy ([Table 1](#t1){ref-type="table"}). Significant differences were only found with regards to history (p = 0.044), tumor size (5.24 ± 2.29 versus 4.74 ± 1.97, p = 0.032), number of LNs retrieved (18.35 ± 9.72 versus 20.80 ± 10.38, p = 0.020), and pT stage (p = 0.044). [Figure 1](#f1){ref-type="fig"} also shows the relationship between the number of metastatic LNs and number of retrieved LNs, number of retrieved LNs and tumor size, number of metastatic LNs and tumor size, number of retrieved LNs and age, and number of metastatic LNs and age.

Univariate analysis identified tumor size (p = 0.019), lymphatic vessel invasion (LVI) (p = 0.002), pT stage (p = 0.002), pN stage (p \< 0.001), and TNM stage (p = 0.001) to significantly correlate with prognosis for the entire population ([Fig. 2](#f2){ref-type="fig"}). Multivariate analysis demonstrated that tumor size (RR 1.474, 95% CI 1.051--2.065, p = 0.024), pT stage (RR 1.260, 95% CI 1.057--1.502, p = 0.010), pN stage (RR 1.187, 95% CI 1.028--1.370, p = 0.020), locoregional recurrence (RR 2.383, 95% CI 1.545--3.676, p \< 0.001), and distant recurrence (RR 2.346, 95% CI 1.563--3.521, p \< 0.001) were independent prognostic factors for the entire population; however, lymphatic vessel invasion and TNM stage were not ([Table 2](#t2){ref-type="table"}).

For the 360 patients with LN metastasis, the univariate analysis identified tumor size (p = 0.021), LVI (p = 0.013), and pT stage (p \< 0.001) as independent factors correlating with LN metastasis ([Table 3](#t3){ref-type="table"}). As shown, the multivariate analysis confirmed that tumor size (RR 1.475, 95% CI 1.035--2.103, p = 0.032) and pT stage (RR 1.444, 95% CI 1.210--1.723, p \< 0.001) were independent prognostic factors predicting LN metastasis ([Table 3](#t3){ref-type="table"}). [Figure 2](#f2){ref-type="fig"} shows survival curves comparing D2 and D2+ lymphadenectomy, tumor size, LVI, pT stage, pN stage, and TNM stage.

When comparing 5-year survival rates of patients who underwent D2 and D2+ lymphadenectomy, as stratified by pT stage and pN stage, a significant difference was found in pN3 patients (33.9% versus 16.3%, log-rank, p = 0.026), but not for pT2--4 and pN0--2 patients, or the patient cohort as a whole (45.4% versus 44.4%, log-rank, p = 0.776; [Table 4](#t4){ref-type="table"}). The survival curves comparing D2 and D2+ lymphadenectomy in patients with pT2--4 and pN0--3 stages are shown in [Figs 3](#f3){ref-type="fig"} and [4](#f4){ref-type="fig"}, respectively.

Discussion
==========

Radical surgery remains the primary potentially curable treatment for patients with resected gastric cancer. Complete resection with a negative margin (R0 resection) has been regarded as the standard goal and subtotal gastrectomy is preferred for patients with distal gastric cancer, as this approach has similar outcomes with significantly fewer complications as compared to total gastrectomy[@b17]. Thus, only patients with distal gastric cancer who underwent subtotal gastrectomy were included in this study.

Recently, D2 lymphadenectomy has become the standard treatment for curable gastric cancer in eastern Asia. Moreover, previous research has shown that patients with advanced gastric cancer benefit from a more extensive LN dissection[@b11]. D2+ lymphadenectomy is known to access more LNs compared with D2 lymphadenectomy, which may contribute to adequate staging and survival benefit. Moreover, D2+ lymphadenectomy has the same morbidity and mortality as D2 lymphadenectomy[@b18]. Therefore, we conducted this study to investigate survival outcome for patients undergoing distal subtotal gastrectomy with D2+ or D2 lymphadenectomy for locally advanced gastric cancer.

Documentation of insufficient number and level of LNs retrieved is recommended by both the UICC and JGCA. Insufficient LN retrieval leads to under-staging, or "stage migration"[@b10]. Both the UICC and JGCA N staging systems recommend retrieving a minimum of 15 LNs. If the number of retrieved LNs is inadequate (\<15), down-staging may occur with residual positive LNs[@b19][@b20]. In this study, the median number of retrieved LNs was 18.35 and 20.80 for D2 and D2+ lymphadenectomy, which was a significant difference although both types of lymphadenectomy achieved an adequate number of retrieved LNs (\>15 LNs).

We purport that LN metastasis is a poor prognostic factor for patients with gastric cancer and that the number of positive LNs significantly influences survival[@b21]. In our cohort, the prevalence of LN metastasis was 86.5% (87.1% in patients with D2 lymphadenectomy and 85.3% in patients with D2+ lymphadenectomy). LN metastasis was more frequently observed in patients with a larger tumor size (≥4 cm), LVI, and a greater depth of invasion (pT stage). The multivariate analysis confirmed tumor size and pT stage as independent factors predicting LN metastasis, indicating that larger tumors with a greater depth of invasion had a higher risk of LN metastasis and therefore a worse survival. Thus, we advise that as many LNs should be retrieved as possible to avoid residual LNs, especially for larger tumors with a greater depth of invasion.

We also confirmed that patients with locally advanced gastric cancer failed to benefit from D2+ lymphadenectomy as compared with D2 lymphadenectomy. In order to investigate the independent factors predicting LN metastasis, univariate and multivariate analyses were conducted. No significant difference was observed between D2 and D2+ lymphadenectomy for patients with LNs metastasis, confirming the fact that D2+ failed to decrease the incidence of LNs metastasis.

When comparing 5-year survival between D2 and D2+ lymphadenectomy for locally advanced gastric cancer, we found no significance between D2 and D2+ lymphadenectomy for the entire patient cohort (45.4% versus 44.4%, p = 0.776) and for those with pT2, pT3, pT4, pN0, pN1, and pN2 stages. Importantly, D2 lymphadenectomy was found to have a superior survival rate compared with D2+ lymphadenectomy in pN3 patients. No 5-year survival benefit was found in patients undergoing D2+ lymphadenectomy compared with D2 lymphadenectomy. Therefore, D2+ lymphadenectomy should not be recommended for patients with locally advanced gastric cancer in eastern Asia.

Our study had several limitations. First, this retrospective study was based on 24-year follow-up data, and the time frame may be too large to be able to adequately address the research question, as patients, surgeons, surgical techniques, surgical scales, skills, and adjuvant therapy have changed. Second, we did not compare surgical complications between patients who underwent D2 and D2+ lymphadenectomy. Third, we didn't include patients with pre-operative chemo-radiation or chemotherapy. The results of our study must be weighed based on these points, which should be clarified in further studies.

In conclusion, we demonstrated that D2+ lymphadenectomy failed to improve survival for patients with locally advanced gastric cancer undergoing distal subtotal gastrectomy, as compared with D2 lymphadenectomy. However, sufficient experience and a high degree of training is required to perform D2 lymphadenectomy. Based on our results, we recommend D2 lymphadenectomy for patients with locally advanced gastric cancer undergoing distal subtotal gastrectomy, especially in eastern Asia.
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###### Clinicopathologic features of patients with D2 and D2+ lymphadenectomy (n = 416).

  Variables                     D2 lymphadenectomy n = 287   D2+ lymphadenectomyn = 129  p value
  ---------------------------- ---------------------------- ---------------------------- ---------
  Sex                                                                                    0.067
   Female                               81 (28.2)                    48 (37.2)            
   Male                                 206 (71.8)                   81 (62.8)            
  Age (years)                         58.61 ± 10.63                57.86 ± 11.07         0.510
  Previous history                                                                       0.044
   Ulcer                                42 (14.6)                    21 (16.3)            
   Gastritis                             23 (8.0)                     12 (9.3)            
   Gastritis and ulcer                   3 (1.1)                      7 (5.4)             
   None                                 219 (76.3)                   89 (69.0)            
  Tumor size (cm)                      5.24 ± 2.29                  4.74 ± 1.97          0.032
  Macroscopic type                                                                       0.801
   Borrmann 1                            7 (2.4)                      2 (1.6)             
   Borrmann 2                           51 (17.8)                    19 (14.7)            
   Borrmann 3                           215 (74.9)                   101 (78.3)           
   Borrmann 4                            14 (4.9)                     7 (5.4)             
  Histologic grade                                                                       0.145
   Well differentiated                  81 (28.2)                    45 (34.9)            
   Moderately differentiated            58 (20.2)                    28 (21.7)            
  Poorly differentiated                 140 (48.8)                   49 (38.0)            
   Undifferentiated                      8 (2.8)                      7 (5.4)             
  Margin status                                                                          0.378
   Negative                             282 (98.3)                   125 (96.9)           
   Positive                              5 (1.7)                      4 (3.1)             
  Venous invasion                                                                        0.901
   Negative                             283 (98.6)                   127 (98.4)           
   Positive                              4 (1.4)                      2 (1.6)             
  Lymphatic vessels invasion                                                             0.087
   Negative                             224 (78.0)                   110 (85.3)           
   Positive                             63 (22.0)                    19 (14.7)            
  Number of LNs retrieved              18.35 ± 9.72                20.80 ± 10.38         0.020
  pT stage                                                                               0.044
   pT2                                  51 (17.8)                    24 (18.6)            
   pT3                                  140 (48.8)                   47 (36.4)            
   pT4                                  96 (33.4)                    58 (45.0)            
  pN stage                                                                               0.667
   pN0                                  37 (12.9)                    19 (14.7)            
   pN1                                  81 (28.2)                    41 (31.8)            
   pN2                                  92 (32.1)                    34 (26.4)            
   pN3                                  77 (26.8)                    35 (27.1)            
  LN metastasis                                                                          0.612
   No                                   37 (12.9)                    19 (14.7)            
   Yes                                  250 (87.1)                   110 (85.3)           
  Number of LNs metastasis             4.92 ± 5.01                  5.37 ± 6.86          0.454
  TNM stage                                                                              0.106
   Stage II                             182 (63.4)                   71 (55.0)            
   Stage III                            105 (36.6)                   58 (45.5)            
  Reconstruction type                                                                    0.170
   Billroth I                           231 (80.5)                   111 (86.0)           
   Billroth II                          56 (19.5)                    18 (14.0)            
  Number of LNs retrieved                                                                0.367
   Inadequate (n \< 15)                 102 (35.5)                   40 (31.0)            
   Adequate (n ≥ 15)                    185 (64.5)                   89 (69.0)            
  Locoregional recurrence                                                                0.286
   Absent                               213 (74.2)                   102 (79.1)           
   Present                              74 (25.8)                    27 (20.9)            
  Distant recurrence                                                                     0.404
   Absent                               186 (64.8)                   89 (69.0)            
   Present                              101 (35.2)                   40 (31.0)            
  Chemotherapy                                                                           0.073
   No                                   193 (67.2)                   98 (76.0)            
   Yes                                  94 (32.8)                    31 (24.0)            

Two tailed t-tests of mean ± standard deviation (SD); n, number of patients; LNs, lymph nodes.

###### Univariate and multivariable analysis of prognostic factors for the entire population (n = 416).

  Variables                     Univariate analysis   Multivariate analysis                         
  ---------------------------- --------------------- ----------------------- ------- -------------- ---------
  Sex                                                         0.374                                      
   Female                           129 (31.0)                                                           
   Male                             287 (69.0)                                                           
  Age (years)                                                 0.153                                      
   \<65                             281 (67.5)                                                           
   ≥65                              135 (32.5)                                                           
  Tumor size (cm)                                             0.019           1.474   1.051-2.065     0.024
   \<4                               81 (19.5)                                                           
   ≥4                               335 (80.5)                                                           
  Macroscopic type                                            0.298                                      
   Borrmann 1                         9 (2.2)                                                            
   Borrmann 2                        70 (16.8)                                                           
   Borrmann 3                       316 (76.0)                                                           
   Borrmann 4                        21 (5.0)                                                            
  Histological grade                                          0.999                                      
   Well differentiated              126 (30.3)                                                           
   Moderately differentiated         86 (20.7)                                                           
   Poorly differentiated            189 (45.4)                                                           
   Undifferentiated                  15 (3.6)                                                            
  Venous invasion                                             0.301                                      
   Negative                         410 (98.6)                                                           
   Positive                           6 (1.4)                                                            
  Lymphatic vessels invasion                                  0.002                                      
   Negative                         334 (80.3)                                                           
   Positive                          82 (19.7)                                                           
  Margin status                                               0.755                                      
   Negative                         407 (97.8)                                                           
   Positive                           9 (2.2)                                                            
  pT stage                                                    0.002           1.260   1.057--1.502    0.010
   pT2                               75 (18.0)                                                           
   pT3                              187 (45.0)                                                           
   pT4                              154 (37.0)                                                           
  pN stage                                                   \<0.001          1.187   1.028--1.370    0.020
   pN0                               56 (13.5)                                                           
   pN1                              122 (29.3)                                                           
   pN2                              126 (30.3)                                                           
   pN3                              112 (26.9)                                                           
  TNM stage                                                   0.001                                      
   Stage II                         253 (60.8)                                                           
   Stage III                        163 (39.2)                                                           
  Lymphadenectomy                                             0.776                                      
   D2                               287 (69.0)                                                           
   D2+                              129 (31.0)                                                           
  Number of LNs retrieved                                     0.578                                      
   Inadequate (n\<15)               142 (34.1)                                                           
   Adequate (n ≥ 15)                274 (65.9)                                                           
  Locoregional recurrence                                    \<0.001          2.383   1.545--3.676   \<0.001
   Absent                           315 (75.7)                                                           
   Present                          101 (24.3)                                                           
  Distant recurrence                                         \<0.001          2.346   1.563--3.521   \<0.001
   Absent                           275 (66.1)                                                           
   Present                          141 (33.9)                                                           

n, number of patients; LNs, lymph nodes; RR, relative risk; 95% CI, 95% confidence interval.

###### Univariate and multivariate analysis of factors predicting LN metastasis (n = 360).

  Variables                     Univariate analysis   Multivariate analysis                                   
  ---------------------------- --------------------- ----------------------- --------- ------- -------------- ---------
  Sex                                                                          0.272                               
   Female                               108                   83.7                                                 
   Male                                 252                   87.8                                                 
  Age (years)                                                                  0.087                               
   \<65                                 243                   86.5                                                 
   ≥65                                  117                   86.7                                                 
  Tumor size (cm)                                                              0.021    1.475   1.035--2.103    0.032
   \<4                                  71                    87.7                                                 
   ≥4                                   289                   86.3                                                 
  Macroscopic type                                                             0.563                               
   Borrmann 1                            9                     100                                                 
   Borrmann 2                           58                    82.9                                                 
   Borrmann 3                           275                   87.0                                                 
   Borrmann 4                           18                    85.7                                                 
  Histological grade                                                           0.935                               
   Well differentiated                  107                   84.9                                                 
   Moderately differentiated            73                    84.9                                                 
   Poorly differentiated                171                   90.5                                                 
   Undifferentiated                      9                    60.0                                                 
  Venous invasion                                                              0.730                               
   Negative                             355                   86.6                                                 
   Positive                              5                    83.3                                                 
  Lymphatic vessels invasion                                                   0.013                               
   Negative                             284                   85.0                                                 
   Positive                             76                    92.7                                                 
  Margin status                                                                0.951                               
   Negative                             352                   86.5                                                 
   Positive                              8                    88.9                                                 
  pT stage                                                                    \<0.001   1.444   1.210-1.723    \<0.001
   pT2                                  70                    93.3                                                 
   pT3                                  175                   93.6                                                 
   pT4                                  115                   74.7                                                 
  Number of LNs retrieved                                                      0.563                               
   Inadequate (n \< 15)                 114                   80.3                                                 
   Adequate (n ≥ 15)                    246                   89.8                                                 
  Lymphadenectomy                                                              0.812                               
   D2                                   250                   87.1                                                 
   D2+                                  110                   85.3                                                 

n, number of patients; LN, lymph node; RR, relative risk; 95% CI, 95% confidence interval.

###### Comparison of overall survival outcomes among patients with D2 and D2+ lymphadenectomy stratifying by pT and pN stage (n = 416).

  Variables            D2 lymphadenectomy  D2+ lymphadenectomy   p value          
  ------------------- -------------------- --------------------- --------- ------ -------
  Entire population           287          45.4                  129       44.4   0.776
  pT stage                                                                        
   pT2                         51          58.2                  24        66.7   0.398
   pT3                        140          47.8                  47        33.1   0.179
   pT4                         96          35.8                  58        43.1   0.652
  pN stage                                                                        
   pN0                         37          60.9                  19        63.2   0.860
   pN1                         81          48.8                  41        51.2   0.906
   pN2                         92          43.1                  34        53.3   0.169
   pN3                         77          33.9                  35        16.3   0.026

n, number of patients; 5-YSR, 5-year survival rate.
